The combination of HER2/neu (also known as ErbB-2) CAR-T cells and oncolytic adenovirus-expressing anti-PD-L1 and IL-2 remarkably improved survival compared with either form of therapy alone in head and neck squamous cell carcinoma xenograft mice [71]. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.